活细胞青霉素结合蛋白的kinact/KI值测定。

IF 3.8 2区 医学 Q2 CHEMISTRY, MEDICINAL
ACS Infectious Diseases Pub Date : 2024-12-13 Epub Date: 2024-12-04 DOI:10.1021/acsinfecdis.4c00370
Joshua D Shirley, Jacob R Gillingham, Kelsie M Nauta, Shivani Diwakar, Erin E Carlson
{"title":"活细胞青霉素结合蛋白的kinact/KI值测定。","authors":"Joshua D Shirley, Jacob R Gillingham, Kelsie M Nauta, Shivani Diwakar, Erin E Carlson","doi":"10.1021/acsinfecdis.4c00370","DOIUrl":null,"url":null,"abstract":"<p><p>Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC<sub>50</sub> values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>, is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> values are typically obtained from <i>in vitro</i> assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> assay to define inhibitor potency for the PBPs in <i>Streptococcus pneumoniae</i> using the fluorescent, activity-based probe, Bocillin-FL. Our results align with <i>in vitro k</i><sub>inact</sub>/<i>K</i><sub>I</sub> data and show a comparable relationship to previously established IC<sub>50</sub> values. These results support the validity of our <i>in vivo k</i><sub>inact</sub>/<i>K</i><sub>I</sub> method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":"4137-4145"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984511/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> Value Determination for Penicillin-Binding Proteins in Live Cells.\",\"authors\":\"Joshua D Shirley, Jacob R Gillingham, Kelsie M Nauta, Shivani Diwakar, Erin E Carlson\",\"doi\":\"10.1021/acsinfecdis.4c00370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC<sub>50</sub> values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub>, is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> values are typically obtained from <i>in vitro</i> assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> assay to define inhibitor potency for the PBPs in <i>Streptococcus pneumoniae</i> using the fluorescent, activity-based probe, Bocillin-FL. Our results align with <i>in vitro k</i><sub>inact</sub>/<i>K</i><sub>I</sub> data and show a comparable relationship to previously established IC<sub>50</sub> values. These results support the validity of our <i>in vivo k</i><sub>inact</sub>/<i>K</i><sub>I</sub> method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.</p>\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":\" \",\"pages\":\"4137-4145\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984511/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acsinfecdis.4c00370\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c00370","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

青霉素结合蛋白(pbp)是细菌酶的一个重要家族,被β-内酰胺类抗生素共价抑制。PBP抑制破坏肽聚糖的生物合成,导致生长和增殖缺陷,并最终导致裂解。IC50值通常被用作酶抑制和抑制剂选择性的描述符,但在时间依赖性共价抑制剂的研究中可能会产生误导。由于这种脱节,二阶速率常数kinact/KI是一个更合适的共价抑制剂效价度量。尽管kinact/KI值是效价测量的金标准,但通常从体外测定中获得,这限制了具有多个同源物(如PBPs)的酶家族的测定通量。因此,我们采用基于活性的荧光探针Bocillin-FL开发了一种全细胞活性/KI检测方法,以确定肺炎链球菌中PBPs抑制剂的效力。我们的结果与体外动力学/KI数据一致,并显示出与先前建立的IC50值的可比关系。这些结果支持了我们的体内kinact/KI方法作为获得一系列PBPs的β-内酰胺效价的手段的有效性,从而使结构-活性关系研究成为可能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
kinact/KI Value Determination for Penicillin-Binding Proteins in Live Cells.

Penicillin-binding proteins (PBPs) are an essential family of bacterial enzymes that are covalently inhibited by the β-lactam class of antibiotics. PBP inhibition disrupts peptidoglycan biosynthesis, which results in deficient growth and proliferation, and ultimately leads to lysis. IC50 values are often employed as descriptors of enzyme inhibition and inhibitor selectivity, but can be misleading in the study of time-dependent, covalent inhibitors. Due to this disconnect, the second-order rate constant, kinact/KI, is a more appropriate metric of covalent-inhibitor potency. Despite being the gold standard measurement of potency, kinact/KI values are typically obtained from in vitro assays, which limits assay throughput if investigating an enzyme family with multiple homologues (such as the PBPs). Therefore, we developed a whole-cell kinact/KI assay to define inhibitor potency for the PBPs in Streptococcus pneumoniae using the fluorescent, activity-based probe, Bocillin-FL. Our results align with in vitro kinact/KI data and show a comparable relationship to previously established IC50 values. These results support the validity of our in vivo kinact/KI method as a means of obtaining β-lactam potency for a suite of PBPs to enable structure-activity relationship studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Infectious Diseases
ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES
CiteScore
9.70
自引率
3.80%
发文量
213
期刊介绍: ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信